AQST News and Press, Aquestive Therapeutics Inc. From 01/13/20

Acasti Pharma (NASDAQ: ACST )  -66%  after  unsuccessful results  from a Phase 3 TRILOGY 1 trial. More news on: Acasti Pharma Inc., Stage Stores, Inc., Five Below, Inc., Stocks on the move, Read more ...

Investors in Aquestive Therapeutics (NASDAQ: AQST ) can breathe a bit easier on the potential FDA nod for Libervant (diazepam) Buccal Film for the potential treatment of intermittent stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that ar...

WARREN, N.J., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients’ unmet needs and solve therapeutic problems, today reported that the U....

Aquestive Therapeutics (NASDAQ: AQST ) is up  13%  premarket on light volume on the heels of its announcement of preliminary Q4 and 2019 revenues of ~$16M and ~$52M, respectively, both above consensus. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Stocks o...

Anticipates full year 2019 preliminary unaudited total revenues to be approximately $52 million, exceeding previously provided full year revenue guidance Anticipates fourth quarter 2019 preliminary unaudited total revenues to be approximately $16 million Expects preliminary unaudited c...

Aquestive Therapeutics ( AQST ) continues to evolve into a promising long-term investment. The company has completed its Libervant rolling NDA and received FDA approval for Exservan in ALS. In addition, Aquestive reported more than 50% growth of Sympazan shipments to retailers in Q3. What is m...

The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with this Read more ...

Gainers:  LMP Automotive (NASDAQ: LMPX ) +95% . More news on: LMP Automotive Holdings, Inc., Sarepta Therapeutics, Inc., Cohen & Company Inc., Stocks on the move, Read more ...

Aethlon Medical (NASDAQ: AEMD )   -45%  on pricing stock offering. More news on: Aethlon Medical, Inc., Aquestive Therapeutics, Inc., Tonix Pharmaceuticals Holding Corp., Stocks on the move, Read more ...

Aquestive Therapeutics (NASDAQ: AQST ) has priced its public offering of 7M common shares at $5.00 per share for gross proceeds of $35M. More news on: Aquestive Therapeutics, Inc., Healthcare stocks news, Read more ...